{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T19:18:43Z","timestamp":1761765523427,"version":"build-2065373602"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asian Journal of Psychiatry"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1016\/j.ajp.2011.12.001","type":"journal-article","created":{"date-parts":[[2012,2,20]],"date-time":"2012-02-20T22:16:21Z","timestamp":1329776181000},"page":"73-82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Are neurocognitive, clinical and social dysfunctions in schizotaxia reversible pharmacologically? Results from the Changsha study"],"prefix":"10.1016","volume":"5","author":[{"given":"William S.","family":"Stone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolu","family":"Hsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony J.","family":"Giuliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liwen","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaochun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingjiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry J.","family":"Seidman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming T.","family":"Tsuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"1994","series-title":"Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)","author":"American Psychiatric Association","key":"10.1016\/j.ajp.2011.12.001_bib0005"},{"year":"1983","series-title":"The Scale for the Assessment of Negative Symptoms (SANS)","author":"Andreasen","key":"10.1016\/j.ajp.2011.12.001_bib0010"},{"year":"1988","series-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","key":"10.1016\/j.ajp.2011.12.001_bib0015"},{"key":"10.1016\/j.ajp.2011.12.001_bib0020","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0920-9964(00)00112-2","article-title":"Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study","volume":"163","author":"Cuesta","year":"2001","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.ajp.2011.12.001_bib0025","series-title":"Early Clinical Intervention and Prevention in Schizophrenia","first-page":"225","article-title":"Is the development of schizophrenia predictable?","author":"Dazzan","year":"2004"},{"year":"1993","series-title":"Symptom Checklist-90-R (SCL-90-R)","author":"Derogatis","key":"10.1016\/j.ajp.2011.12.001_bib0030"},{"key":"10.1016\/j.ajp.2011.12.001_bib0035","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1176\/ps.2009.60.11.1468","article-title":"Cognitive enhancement therapy for early-course schizophrenia: effects of a 2-year randomized controlled trial","volume":"60","author":"Eack","year":"2009","journal-title":"Psychiatry Serv."},{"key":"10.1016\/j.ajp.2011.12.001_bib0040","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.schres.2010.03.042","article-title":"One-year durability of the effects of cognitive enhancement therapy on functional outcome in early schizophrenia","volume":"120","author":"Eack","year":"2010","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.ajp.2011.12.001_bib0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/oxfordjournals.schbul.a006849","article-title":"Schizotaxia: clinical implications and new directions for research","volume":"27","author":"Faraone","year":"2001","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.ajp.2011.12.001_bib0050","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1192\/bjp.bp.105.016998","article-title":"Psychopathology, personality traits, and social development of adolescent and young adult first-degree relatives of schizophrenia patients","volume":"189","author":"Glatt","year":"2006","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.ajp.2011.12.001_bib0055","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1176\/appi.ajp.2009.09040497","article-title":"Targeting cognition in schizophrenia research: from etiology to treatment","volume":"166","author":"Goldberg","year":"2009","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ajp.2011.12.001_bib0060","series-title":"Schizophrenia","first-page":"142","article-title":"Neurocognitive impairments in schizophrenia: their character and role in symptom formation","author":"Goldberg","year":"2011"},{"key":"10.1016\/j.ajp.2011.12.001_bib0065","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/hup.1070","article-title":"Associations between plasma levels of 3-methoxy-4-hydroxyphenylglycol (MHPG) and negative symptoms or cognitive impairments in early-stage schizophrenia","volume":"24","author":"Goto","year":"2009","journal-title":"Hum. Psychopharmcaol."},{"key":"10.1016\/j.ajp.2011.12.001_bib0070","series-title":"Reading and Understanding More Multivariate Statistics","first-page":"147","article-title":"Cluster analysis","author":"Hair","year":"2000"},{"key":"10.1016\/j.ajp.2011.12.001_bib0075","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.clinthera.2008.09.014","article-title":"Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder","volume":"30","author":"Houthoofd","year":"2008","journal-title":"Clin. Therapy"},{"year":"1990","series-title":"Finding Groups in Data","author":"Kaufman","key":"10.1016\/j.ajp.2011.12.001_bib0080"},{"key":"10.1016\/j.ajp.2011.12.001_bib0085","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archpsyc.64.6.633","article-title":"Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial","volume":"64","author":"Keefe","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.ajp.2011.12.001_bib0090","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1176\/ajp.2007.164.7.1061","article-title":"Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison","volume":"164","author":"Keefe","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ajp.2011.12.001_bib0095","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/schbul\/15.4.559","article-title":"The structured interview for schizotypy (SIS): a preliminary report","volume":"15","author":"Kendler","year":"1989","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.ajp.2011.12.001_bib0100","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.schres.2008.03.006","article-title":"Psychopathology among offspring of parents with schizophrenia: relationship to premorbid impairments","volume":"103","author":"Keshavan","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.ajp.2011.12.001_bib0105","first-page":"62","article-title":"Premorbid cognitive deficits in young relatives of schizophrenia patients","volume":"3","author":"Keshavan","year":"2010","journal-title":"Frontiers Hum. Neurosci."},{"key":"10.1016\/j.ajp.2011.12.001_bib0110","doi-asserted-by":"crossref","first-page":"628","DOI":"10.4088\/JCP.v64n0602","article-title":"Risperidone in the treatment of schizotypal personality disorder","volume":"64","author":"Koenigsberg","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ajp.2011.12.001_bib0115","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.schres.2004.02.022","article-title":"Heterogeneity of schizophrenia: a study of individual neuropsychological profiles","volume":"71","author":"Kremen","year":"2004","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.ajp.2011.12.001_bib0120","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1037\/h0041029","article-title":"Schizotaxia, schizotypy, schizophrenia","volume":"17","author":"Meehl","year":"1962","journal-title":"Am. Psychol."},{"key":"10.1016\/j.ajp.2011.12.001_bib0125","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/archpsyc.1994.03950110009002","article-title":"Diagnostic interview for genetic studies. Rationale, unique features, and training","volume":"51","author":"Nurnberger","year":"1994","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.ajp.2011.12.001_bib0130","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.schres.2009.08.016","article-title":"The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial","volume":"115","author":"Penn","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.ajp.2011.12.001_bib0135","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/hup.863","article-title":"Long-term administration of low-dose risperidone in schizotaxia subjects","volume":"22","author":"Rybakowski","year":"2007","journal-title":"Hum. Psychopharmacol."},{"year":"2008","series-title":"SPSS for Windows, Release 16","author":"SPSS","key":"10.1016\/j.ajp.2011.12.001_bib0140"},{"key":"10.1016\/j.ajp.2011.12.001_bib0145","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/schbul\/sbm041","article-title":"Towards a model of memory enhancement in schizophrenia: glucose administration and hippocampal function","volume":"34","author":"Stone","year":"2008","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.ajp.2011.12.001_bib0150","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0006-3223(01)01116-7","article-title":"Concurrent validation of schizotaxia: a pilot study","volume":"50","author":"Stone","year":"2001","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.ajp.2011.12.001_bib0155","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1089\/cap.2005.15.403","article-title":"Searching for the liability to schizophrenia: concepts and methods underlying genetic high-risk studies of adolescents. J Child","volume":"15","author":"Stone","year":"2005","journal-title":"Adolescent Psychopharmacol."},{"key":"10.1016\/j.ajp.2011.12.001_bib0160","article-title":"Neurocognitive and clinical dysfunction in adult Chinese, nonpsychotic relatives of patients with schizophrenia: Findings from the Changsha study and evidence for schizotaxia","author":"Stone","year":"2011","journal-title":"Asian J. Psychiatry"},{"key":"10.1016\/j.ajp.2011.12.001_bib0165","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/hrp\/7.4.185","article-title":"Schizophrenia: a review of genetic studies","volume":"7","author":"Tsuang","year":"1999","journal-title":"Harvard Rev. Psychiatry"},{"key":"10.1016\/j.ajp.2011.12.001_bib0170","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/S0006-3223(98)00364-3","article-title":"Treatment of nonpsychotic relatives of patients with schizophrenia: four case studies","volume":"41","author":"Tsuang","year":"1999","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.ajp.2011.12.001_bib0175","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1176\/appi.ajp.157.7.1041","article-title":"Towards reformulating the diagnosis of schizophrenia","volume":"147","author":"Tsuang","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ajp.2011.12.001_bib0180","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/ajmg.10363","article-title":"Treatment of nonpsychotic relatives of patients with schizophrenia: six case studies","volume":"114","author":"Tsuang","year":"2002","journal-title":"Am. J. Med. Genet. (Neuropsychiatric Gen.)"},{"key":"10.1016\/j.ajp.2011.12.001_bib0185","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1001\/archpsyc.1976.01770090101010","article-title":"Assessment of social adjustment by patient self-report","volume":"33","author":"Weissman","year":"1976","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.ajp.2011.12.001_bib0190","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1017\/S146114570500516X","article-title":"A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia","volume":"8","author":"Woodward","year":"2005","journal-title":"Int. J. Neuropsychopharmacol."}],"container-title":["Asian Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876201811001560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876201811001560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T16:23:35Z","timestamp":1761755015000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876201811001560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S1876201811001560"],"URL":"https:\/\/doi.org\/10.1016\/j.ajp.2011.12.001","relation":{},"ISSN":["1876-2018"],"issn-type":[{"type":"print","value":"1876-2018"}],"subject":[],"published":{"date-parts":[[2012,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Are neurocognitive, clinical and social dysfunctions in schizotaxia reversible pharmacologically? Results from the Changsha study","name":"articletitle","label":"Article Title"},{"value":"Asian Journal of Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajp.2011.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}